Influenza SARS-CoV-2 Multiplex ValuPanel Reagents

The Influenza SARS-CoV-2 Multiplex ValuPanel™ Reagents are separately delivered probes and primers for RT-PCR detection of the genetic sequences of SARS-CoV-2, influenza A, and influenza B viruses.

For Research Use Only. Not for use in diagnostic procedures. This product may not be used under the U.S. Food and Drug Administration’s (FDA) Emergency Use Authorization (EUA) of the Center for Disease Control and Prevention (CDC) Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay. The oligonucleotide sequences were designed by the CDC.

Key benefits

• Fast delivery: Product in stock ships same or next business day
• Gold standard quencher: From the trusted inventor and original source of Black Hole Quencher™ (BHQ™) technology referenced in 7 of 8 WHO protocols
• Quality manufacture: All probes and primers are HPLC purified and are manufactured and shipped from a facility entirely separate from positive control production.

order now in the
new transaction portal

The Influenza SARS-CoV-2 Multiplex ValuPanel comprises probes and primers based on the following genetic signatures:

• SARS-CoV-2 nucleocapsid (N)

• Influenza A virus matrix (M1)

• Influenza B virus Nonstructural 2 (NS2)

• Human RNase P (extraction control)

The oligonucleotide sequences were designed by the CDC as listed on the CDC RUO primer and probe sequence website. Please note that this product, the Influenza SARS-CoV-2 Multiplex ValuPanel, may not be used under the FDA EUA for the CDC Flu SC2 Multiplex Assay.

For detailed instructions of how to resuspend and premix the ValuPanel probes and primers, please see the quick guide.

order now in the
new transaction portal

Important note: The use of ROX normalisation is not compatible with this panel

Please be aware that master mixes containing ROX passive reference dye should not be used with this panel. This is because the probe for SARS-CoV-2 (cat. no SC2-FSC2-P) is modified with CAL Fluor Red 610 dye, which is detected in the same channel as ROX dye.

If your instrument requires ROX normalisation, please contact the Scientific Services Team for assistance with custom multiplex assay development.

The performance of LGC, Biosearch Technologies’ Influenza SARS-CoV-2 ValuPanel is equivalent to that of the CDC Flu SC2 Multiplex Assay.

Real-time RT-PCR results (Ct) demonstrate the equivalent performance of the Biosearch Technologies assay (Influenza SARS-CoV-2 Multiplex ValuPanel) and the CDC assay (CDC Flu SC2 Multiplex Assay published in the U.S. FDA-authorized IFU LB-122 Rev 01 Effective Date: 21 September 2020). Across a range of target copy numbers (5, 50 and 500 copies), for each assay (InfA, InfB, SC2, and RP), the LGC assay chemistry reaches the detection threshold within +/- 1  cycle of the published CDC assay chemistry. 

Suggested probe and primer quantities to support 5,000 or 20,000 tests

Based on a 20 uL reaction volume with oligonucleotide concentrations as specified in the CDC Flu SC2 Multiplex Assay Instructions For Use (LB-122 Rev 01, effective 21 September 2020)

PCR reagents* including master mix and enzyme for SARS-CoV-2 assay development are also available

For a complete SARS-CoV-2 Quality Solution, consider the AccuPlex™ SARS-CoV-2 Verification Panel coupled with the AccuPlex™ SARS-CoV-2 Reference Material Kit from LGC SeraCare Life Sciences. The target sequence of interest is packaged into a stable non-infectious, and replication-deficient alphavirus particle and the products contain positive materials directed against the published CDC and WHO consensus sequences and the S gene. Also includes negative materials targeting the human RNase P gene.

*For Research Use Only. Not for use in diagnostic procedures.